Natural hotspots are pockets that are decisive in protein function. HotSpot uses the Smart Allostery platform to identify natural hotspots in disease-relevant proteins. HotsSpot has successfully identified selective small molecule inhibitors of E3 ubiquitin ligase and CBL-B using the platform, and it has demonstrated that these small molecules promote T-cell responses in vitro and in mice.

The investors included in the series C round included Pivotal Bioventure Partners, LSP and B Capital Group, Monashee Investment Management, CaaS Capital Management, Revelation Partners, Pavilion Capital, Atlas Venture, Sofinnova Partners, SR One Capital Management, Tekla Capital Management, and MRL Ventures Fund.

Cancer Cell Map Initiative reveals protein interactions that drive cancer
A research group has mapped previously unknown interactions between proteins that drive cancer, thereby revealing potential new biomarkers and drug targets....